ATE173760T1 - Verfahren zur herstellung von lebenden zellkulturen, die durch einen multiple sklerose assoziierten virus infiziert sind - Google Patents

Verfahren zur herstellung von lebenden zellkulturen, die durch einen multiple sklerose assoziierten virus infiziert sind

Info

Publication number
ATE173760T1
ATE173760T1 AT93908990T AT93908990T ATE173760T1 AT E173760 T1 ATE173760 T1 AT E173760T1 AT 93908990 T AT93908990 T AT 93908990T AT 93908990 T AT93908990 T AT 93908990T AT E173760 T1 ATE173760 T1 AT E173760T1
Authority
AT
Austria
Prior art keywords
infected
culture
multiple sclerosis
cell cultures
associated virus
Prior art date
Application number
AT93908990T
Other languages
English (en)
Inventor
Herve Perron
Jean-Marie Seigneurin
Original Assignee
Bio Merieux
Univ Grenoble 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9204322A external-priority patent/FR2689519B1/fr
Application filed by Bio Merieux, Univ Grenoble 1 filed Critical Bio Merieux
Application granted granted Critical
Publication of ATE173760T1 publication Critical patent/ATE173760T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT93908990T 1992-04-03 1993-04-02 Verfahren zur herstellung von lebenden zellkulturen, die durch einen multiple sklerose assoziierten virus infiziert sind ATE173760T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9204322A FR2689519B1 (fr) 1992-04-03 1992-04-03 Procédé de culture in vitro de cellules infectées par un virus associé à la sclérose en plaques et lignées cellulaires obtenues.
FR9213447A FR2689521B1 (fr) 1992-04-03 1992-11-03 Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.

Publications (1)

Publication Number Publication Date
ATE173760T1 true ATE173760T1 (de) 1998-12-15

Family

ID=26229389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93908990T ATE173760T1 (de) 1992-04-03 1993-04-02 Verfahren zur herstellung von lebenden zellkulturen, die durch einen multiple sklerose assoziierten virus infiziert sind

Country Status (8)

Country Link
US (2) US5585262A (de)
EP (1) EP0592636B1 (de)
AT (1) ATE173760T1 (de)
CA (1) CA2110702C (de)
DE (1) DE69322227T2 (de)
DK (1) DK0592636T3 (de)
FR (1) FR2689521B1 (de)
WO (1) WO1993020189A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
FR2689520B1 (fr) 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
AU704440B2 (en) * 1994-02-04 1999-04-22 Bio Merieux MSRV1 virus and MSRV2 pathogenic and/or infectious agent associated with multiple sclerosis, nucleic acid components and applications of same
FR2716198B1 (fr) * 1994-02-15 1996-04-19 Bio Merieux Facteur cytotoxique tel qu'associé à la sclérose en plaques, sa détection et sa quantification.
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
EP0942987B1 (de) * 1996-11-26 2009-08-19 Bio Merieux Virales material und mit multipler sklerose assoziierte nukleotidfragmente mit diagnostischen, prophylaktischen und therapeutischen verwendungen
FR2765588A1 (fr) 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
WO2025074921A1 (ja) * 2023-10-06 2025-04-10 株式会社微生物化学研究所 ウイルスの生産方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) * 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US4311686A (en) * 1979-04-30 1982-01-19 The Immunology Development Corporation Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) * 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
NZ218050A (en) * 1985-11-13 1989-05-29 Wistar Inst Test for the presence of htlv-1v
US4900553A (en) * 1987-09-11 1990-02-13 Case Western Reserve University Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (de) * 1988-01-29 1989-08-02 City Of Hope Verfahren zum Nachweis und zur Identifizierung von bestimmten viralen Sequenzien
FR2651581B1 (fr) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
DK173091D0 (da) * 1991-10-11 1991-10-11 Schleroseforeningen The Danish Biologisk materiale
FR2689520B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
CA2117893A1 (en) * 1992-05-18 1993-11-25 Paul J. Godowski Variant dimers for receptor activation
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus

Also Published As

Publication number Publication date
FR2689521B1 (fr) 1996-07-19
CA2110702C (fr) 2004-06-22
DE69322227T2 (de) 1999-04-22
US5925555A (en) 1999-07-20
DE69322227D1 (de) 1999-01-07
FR2689521A1 (fr) 1993-10-08
WO1993020189A1 (fr) 1993-10-14
DK0592636T3 (da) 1999-08-09
EP0592636B1 (de) 1998-11-25
US5585262A (en) 1996-12-17
CA2110702A1 (fr) 1993-10-14
EP0592636A1 (de) 1994-04-20

Similar Documents

Publication Publication Date Title
ATE161041T1 (de) Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten
ATE231729T1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
AU588885B2 (en) Production of viral antigens
HUP9900920A2 (hu) Eljárás emlőssejt-tenyészetekben termelt proteinek szializációjának szabályozására
DE69333855D1 (de) Aus einer mit einem Stamm von Multiple-Sklerosis-Virus infizierten Zellinie hergestelltes biologisches Virusmaterial
DE69533941D1 (de) Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
MX9202992A (es) Factor de estimulacion de colonias de granulocitos pluripotenciales de un mamifero y proceso biotecnologico para su produccion.
NO164111C (no) Fremgangsmaate for fremstilling av et antibiotisk virksomta 40926-kompleks og dets rene faktorer pa, pb, a, b og bomikron.
DE69322227D1 (de) Verfahren zur herstellung von lebenden zellkulturen, die durch einen multiple sklerose assoziierten virus infiziert sind
ES469937A1 (es) Procedimiento para preparar una nueva cepa del virus de la rabia.
ES8105930A1 (es) Procedimiento para la preparacion de vacunas de virus poli- valentes
Storz et al. On enteropathogenic bovine coronavirus
EP0896059A3 (de) Verfahren zur Erzeugung von pathogen-resistenten Pflanzen
ES385968A1 (es) Metodo para producir una vacuna de virus de enfermedad de newcastle muy atenuado.
ATE83504T1 (de) Enzymsystem, sein herstellungsverfahren und seine verwendung, insbesondere bei der herstellung von d-parahydroxyphenylglycin.
GB1358321A (en) Method od tissue cell culture
JPS5774093A (en) Method of increasing interferon production
DE3484206D1 (de) Verfahren zur herstellung von l-glutaminsaeure durch fermentation und dazu zu verwendende mutante mikroorganismen.
AU6262786A (en) Growing aids virus in cell lines lacking human class ii histocompatability antigens
JPS5534017A (en) Preparation of itaconic acid
ATE148896T1 (de) Verfahren zur herstellung von gluratimid- copolymeren und zwischenprodukte dafür
WO1994011518A3 (en) Methods for converting a, ab, and b blood types to o blood type
JPS5571491A (en) Preparation of proline acylase
DE3779444T2 (de) Impfstoff gegen herpes simplex.
DE59008891D1 (de) Verfahren zur herstellung eines regulationsproteins (nef) von hiv-1 unter verwendung der humanen zellinie th4-7-5.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties